Stefan Rehnmark
Direttore Tecnico/Scientifico/R&S presso GABATHER AB
Posizioni attive di Stefan Rehnmark
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| GABATHER AB | Direttore Tecnico/Scientifico/R&S | 01/01/2018 | - |
| Corporate Officer/Principal | 01/08/2016 | 01/01/2018 | |
| LIDDS AB | Direttore/Membro del Consiglio | 27/05/2024 | - |
Storia della carriera di Stefan Rehnmark
Precedenti posizioni note di Stefan Rehnmark
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| University of Stockholm | Corporate Officer/Principal | 01/01/1998 | 01/01/1998 |
| Noviga Research AB | Fondatore | - | - |
Axcentua Pharmaceuticals AB
 Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Amministratore Delegato | - | - |
| Direttore Tecnico/Scientifico/R&S | - | - | |
| Fondatore | 01/01/2007 | - |
Formazione di Stefan Rehnmark
| University of Stockholm | Doctorate Degree |
Statistiche
Distribuzione geografica
| Svezia | 6 |
Posizioni
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
| Founder | 2 |
Settori
| Health Technology | 4 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| GABATHER AB | Health Technology |
| LIDDS AB | Health Technology |
| Aziende private | 2 |
|---|---|
Axcentua Pharmaceuticals AB
Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Health Technology |
| Noviga Research AB |
- Borsa valori
- Insiders
- Stefan Rehnmark
- Esperienza
